Literature DB >> 28470594

How to Appropriately Extrapolate Costs and Utilities in Cost-Effectiveness Analysis.

Laura Bojke1, Andrea Manca2, Miqdad Asaria2, Ronan Mahon2, Shijie Ren3, Stephen Palmer2.   

Abstract

Costs and utilities are key inputs into any cost-effectiveness analysis. Their estimates are typically derived from individual patient-level data collected as part of clinical studies the follow-up duration of which is often too short to allow a robust quantification of the likely costs and benefits a technology will yield over the patient's entire lifetime. In the absence of long-term data, some form of temporal extrapolation-to project short-term evidence over a longer time horizon-is required. Temporal extrapolation inevitably involves assumptions regarding the behaviour of the quantities of interest beyond the time horizon supported by the clinical evidence. Unfortunately, the implications for decisions made on the basis of evidence derived following this practice and the degree of uncertainty surrounding the validity of any assumptions made are often not fully appreciated. The issue is compounded by the absence of methodological guidance concerning the extrapolation of non-time-to-event outcomes such as costs and utilities. This paper considers current approaches to predict long-term costs and utilities, highlights some of the challenges with the existing methods, and provides recommendations for future applications. It finds that, typically, economic evaluation models employ a simplistic approach to temporal extrapolation of costs and utilities. For instance, their parameters (e.g. mean) are typically assumed to be homogeneous with respect to both time and patients' characteristics. Furthermore, costs and utilities have often been modelled to follow the dynamics of the associated time-to-event outcomes. However, cost and utility estimates may be more nuanced, and it is important to ensure extrapolation is carried out appropriately for these parameters.

Entities:  

Keywords:  Baseline Utility; Decision Uncertainty; Health Assessment Questionnaire Score; Individual Patient Data; Psoriasis Area Severity Index

Mesh:

Year:  2017        PMID: 28470594     DOI: 10.1007/s40273-017-0512-6

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  44 in total

Review 1.  Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.

Authors:  N Woolacott; Y Bravo Vergel; N Hawkins; A Kainth; Z Khadjesari; K Misso; K Light; C Asseburg; S Palmer; K Claxton; I Bruce; M Sculpher; R Riemsma
Journal:  Health Technol Assess       Date:  2006-09       Impact factor: 4.014

Review 2.  Dronedarone for the treatment of atrial fibrillation and atrial flutter.

Authors:  E Maund; C McKenna; M Sarowar; D Fox; M Stevenson; C Pepper; S Palmer; N Woolacott
Journal:  Health Technol Assess       Date:  2010-10       Impact factor: 4.014

Review 3.  The clinical effectiveness and cost-effectiveness of topotecan for small cell lung cancer: a systematic review and economic evaluation.

Authors:  E Loveman; J Jones; D Hartwell; A Bird; P Harris; K Welch; A Clegg
Journal:  Health Technol Assess       Date:  2010-03       Impact factor: 4.014

Review 4.  Unrelated medical costs in life-years gained: should they be included in economic evaluations of healthcare interventions?

Authors:  David R Rappange; Pieter H M van Baal; N Job A van Exel; Talitha L Feenstra; Frans F H Rutten; Werner B F Brouwer
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

Review 5.  Health technology funding decision-making processes around the world: the same, yet different.

Authors:  Tania Stafinski; Devidas Menon; Donald J Philippon; Christopher McCabe
Journal:  Pharmacoeconomics       Date:  2011-06       Impact factor: 4.981

6.  Perspectives in economic evaluation.

Authors:  S Byford; J Raftery
Journal:  BMJ       Date:  1998-05-16

7.  Clinical effectiveness and cost-effectiveness of surgical options for the management of anterior and/or posterior vaginal wall prolapse: two randomised controlled trials within a comprehensive cohort study - results from the PROSPECT Study.

Authors:  Cathryn Glazener; Suzanne Breeman; Andrew Elders; Christine Hemming; Kevin Cooper; Robert Freeman; Anthony Smith; Suzanne Hagen; Isobel Montgomery; Mary Kilonzo; Dwayne Boyers; Alison McDonald; Gladys McPherson; Graeme MacLennan; John Norrie
Journal:  Health Technol Assess       Date:  2016-12       Impact factor: 4.014

8.  The effectiveness and cost-effectiveness of minimal access surgery amongst people with gastro-oesophageal reflux disease - a UK collaborative study. The REFLUX trial.

Authors:  A Grant; S Wileman; C Ramsay; L Bojke; D Epstein; M Sculpher; S Macran; M Kilonzo; L Vale; J Francis; A Mowat; Z Krukowski; R Heading; M Thursz; I Russell; M Campbell
Journal:  Health Technol Assess       Date:  2008-09       Impact factor: 4.014

9.  Accounting for uncertainty in health economic decision models by using model averaging.

Authors:  Christopher H Jackson; Simon G Thompson; Linda D Sharples
Journal:  J R Stat Soc Ser A Stat Soc       Date:  2009-04       Impact factor: 2.483

10.  The costs of inequality: whole-population modelling study of lifetime inpatient hospital costs in the English National Health Service by level of neighbourhood deprivation.

Authors:  Miqdad Asaria; Tim Doran; Richard Cookson
Journal:  J Epidemiol Community Health       Date:  2016-05-17       Impact factor: 3.710

View more
  4 in total

1.  Cancer Incidence Trends From 1999 to 2015 And Contributions Of Various Cancer Types To The Overall Burden: Projections To 2030 And Extrapolation Of Economic Burden In Saudi Arabia.

Authors:  Abdul Rahman Jazieh; Omar B Da'ar; Mohammad Alkaiyat; Yasmine A Zaatreh; Aida A Saad; Rami Bustami; Mashael Alrujaib; Khaled Alkattan
Journal:  Cancer Manag Res       Date:  2019-11-14       Impact factor: 3.989

2.  Lifetime Costs of Surviving Cancer-A Queensland Study (COS-Q): Protocol of a Large Healthcare Data Linkage Study.

Authors:  Katharina M D Merollini; Louisa G Gordon; Joanne F Aitken; Michael G Kimlin
Journal:  Int J Environ Res Public Health       Date:  2020-04-20       Impact factor: 3.390

3.  The Burden, Future Trends, And Economic Impact Of Lung Cancer In Saudi Arabia.

Authors:  Omar B Da'ar; Yasmine A Zaatreh; Aida A Saad; Mohammad Alkaiyat; Tabrez Pasha; Anwar E Ahmed; Rami Bustami; Khaled Alkattan; Abdul Rahman Jazieh
Journal:  Clinicoecon Outcomes Res       Date:  2019-11-19

4.  Longitudinal assessment of utilities in patients with migraine: an analysis of erenumab randomized controlled trials.

Authors:  Gian Luca Di Tanna; Joshua K Porter; Richard B Lipton; Anthony J Hatswell; Sandhya Sapra; Guillermo Villa
Journal:  Health Qual Life Outcomes       Date:  2019-11-12       Impact factor: 3.186

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.